News

AdnaGen, a subsidiary of OncoVista Innovative Therapies, a global biotech company developing proprietary, early detection and drug technologies, has entered into an option agreement to license specific antibodies

Activus’ core technologies in drug formulation using proprietary nano-particle processing is expected to form the basis of Sosei’s new platform technology. Activus Pharma said that its Activus Pure

XL184, a clinically advanced MET inhibitor, is a collaborative effort of Exelixis and Bristol-Myers Squibb (BMS). Exelixis and BMS entered into development collaboration in December 2008. As per

GW Pharma claimed that Sativex is the first prescription cannabis medicine and the UK is the first country to grant a full regulatory authorisation for the product. GW

In the new facility, space will be dedicated for automatic and manual visual inspection, as well as for stability chambers designed to the standards. Vetter claims that the

The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing

Mr Sharpington has nearly 20 years’ experience in the life sciences sector with various biotechnology and pharmaceutical service companies in Europe and the US. He has broad experience

Mr Unsworth will succeed David Edwards, who will continue to advise the company during a transition period. Mr Unsworth served as president of Asia-Pacific, for Schering-Plough from 2004

OncoGenex Pharma said that this trial is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva